Mosanna Therapeutics

Mosanna Therapeutics is a private, preclinical-stage biotech pioneering a first-in-class pharmaceutical treatment for obstructive sleep apnea (OSA). Its lead program is a nasal spray designed to reactivate the upper airway muscles during sleep, offering a potential alternative to CPAP machines and other mechanical interventions. Backed by a veteran leadership team with extensive drug development and regulatory experience, the company is positioned to address a massive, underserved market with a therapy focused on biological restoration rather than physical force.

Pharmacological nasal spray designed to reactivate the body's natural upper airway muscle control during sleep, targeting the neurobiological pathways that fail in obstructive sleep apnea.

Competition primarily comes from established medical device companies (e.g., ResMed, Philips) improving CPAP comfort, and a handful of other biotechs exploring drug treatments for sleep apnea (e.g., Apnimed). Mosanna's differentiation lies in its specific nasal delivery and focus on restoring natural airway reflexes.